The impact of the immune system on the safety and efficiency of enzyme replacement therapy in lysosomal storage disorders (Q87305419)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883220%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

title

The impact of the immune system on the safety and efficiency of enzyme replacement therapy in lysosomal storage disorders (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883220%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883220%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Simon Jones

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883220%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Brian Bigger

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883220%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

S M Hughes

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883220%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

publication date

16 February 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883220%20AND%20SRC:MED&resulttype=core&format=json

Journal of Inherited Metabolic Disease

8 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883220%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

volume

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883220%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883220%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

page(s)

499-512

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883220%20AND%20SRC:MED&resulttype=core&format=json

Tregitope: Immunomodulation powerhouse

8 March 2020

cites work

1 reference

12 December 2020

Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-ac

1 reference

12 December 2020

Anti-α-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry

1 reference

12 December 2020

Involvement of the TNF-α/TGF-β/IDO axis in IVIg-induced immune tolerance.

1 reference

12 December 2020

Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I.

1 reference

12 December 2020

The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease

1 reference

12 December 2020

Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study

1 reference

12 December 2020

Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I.

1 reference

12 December 2020

Induction of Immune Tolerance to a Therapeutic Protein by Intrathymic Gene Delivery

1 reference

12 December 2020

Longitudinal observations of serum heparin cofactor II-thrombin complex in treated Mucopolysaccharidosis I and II patients

1 reference

12 December 2020

Genetic risk factors for inhibitors to factors VIII and IX.

1 reference

12 December 2020

Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience

1 reference

12 December 2020

Biomarker responses correlate with antibody status in mucopolysaccharidosis type I patients on long-term enzyme replacement therapy

1 reference

12 December 2020

Mapping the T helper cell response to acid α-glucosidase in Pompe mice

1 reference

12 December 2020

Long-term safety and efficacy of rituximab in 7 Japanese patients with ANCA-associated vasculitis

1 reference

12 December 2020

Immunogenicity of protein therapeutics

1 reference

12 December 2020

Multidisciplinary management of Hunter syndrome.

1 reference

12 December 2020

Tuning microenvironments: induction of regulatory T cells by dendritic cells

1 reference

12 December 2020

Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase.

1 reference

12 December 2020

Identification of a receptor required for the anti-inflammatory activity of IVIG.

1 reference

12 December 2020

Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes

1 reference

12 December 2020

Repeated intrathecal injections of recombinant human 4-sulphatase remove dural storage in mature mucopolysaccharidosis VI cats primed with a short-course tolerisation regimen

1 reference

12 December 2020

Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products

1 reference

12 December 2020

Mechanisms of action of cyclosporine.

1 reference

12 December 2020

Understanding TR binding to pMHC complexes: how does a TR scan many pMHC complexes yet preferentially bind to one.

1 reference

12 December 2020

Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I

1 reference

12 December 2020

Self-representation in the thymus: an extended view

1 reference

12 December 2020

Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg

1 reference

12 December 2020

Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models.

1 reference

12 December 2020

Innate B cell helpers reveal novel types of antibody responses.

1 reference

12 December 2020

Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals

1 reference

12 December 2020

Comparison of neutralizing antibody assays for receptor binding and enzyme activity of the enzyme replacement therapeutic Naglazyme (galsulfase).

1 reference

12 December 2020

Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease.

1 reference

12 December 2020

Modulating dendritic cells (DC) from immunogenic to tolerogenic responses: a novel mechanism of AZA/6-MP.

1 reference

12 December 2020

BAFF blockade prevents anti-drug antibody formation in a mouse model of Pompe disease

1 reference

12 December 2020

Overview of complement activation and regulation

1 reference

12 December 2020

Mucopolysaccharide diseases: a complex interplay between neuroinflammation, microglial activation and adaptive immunity.

1 reference

12 December 2020

Enzyme replacement therapy in Fabry disease: a randomized controlled trial

1 reference

12 December 2020

Fabry disease peripheral blood immune cells release inflammatory cytokines: role of globotriaosylceramide

1 reference

12 December 2020

Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease

1 reference

12 December 2020

Successful desensitization to imiglucerase of an adult patient diagnosed with type I Gaucher disease.

1 reference

12 December 2020

Gaucher disease: genetic heterogeneity within and among the subtypes detected by immunoblotting

1 reference

12 December 2020

Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease

1 reference

12 December 2020

Antigen Presentation, Autoantigens, and Immune Regulation in Multiple Sclerosis and Other Autoimmune Diseases

1 reference

12 December 2020

Regulatory T cells and Foxp3

1 reference

12 December 2020

Hypersensitivity reactions to biological drugs

1 reference

12 December 2020

Successful immune tolerance induction by FVIII in hemophilia A patients with inhibitor may occur without deletion of FVIII-specific T cells.

1 reference

12 December 2020

Administration of anti-CD3 antibodies modulates the immune response to an infusion of α-glucosidase in mice

1 reference

12 December 2020

Oral delivery of Acid Alpha Glucosidase epitopes expressed in plant chloroplasts suppresses antibody formation in treatment of Pompe mice

1 reference

12 December 2020

Aggregated recombinant human interferon Beta induces antibodies but no memory in immune-tolerant transgenic mice.

1 reference

12 December 2020

Identification and removal of immunogenicity in therapeutic proteins.

1 reference

12 December 2020

A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease

1 reference

12 December 2020

Natural versus adaptive regulatory T cells

1 reference

12 December 2020

Immunological responses to exogenous insulin

1 reference

12 December 2020

The molecular mechanisms of immunomodulation and tolerance induction to factor VIII.

1 reference

12 December 2020

Impact of product-related factors on immunogenicity of biotherapeutics

1 reference

12 December 2020

Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction.

1 reference

12 December 2020

Inhibitor recurrence after immune tolerance induction: a multicenter retrospective cohort study

1 reference

12 December 2020

Human cells: new platform for recombinant therapeutic protein production

1 reference

12 December 2020

Enzyme therapy of gaucher disease: clinical and biochemical changes during production of and tolerization for neutralizing antibodies.

1 reference

12 December 2020

Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products

1 reference

12 December 2020

Regulation of immune responses to protein therapeutics by transplacental induction of T cell tolerance

1 reference

12 December 2020

Immune modulation in Pompe disease treated with enzyme replacement therapy

1 reference

12 December 2020

Sleep disordered breathing in mucopolysaccharidosis I: a multivariate analysis of patient, therapeutic and metabolic correlators modifying long term clinical outcome.

1 reference

12 December 2020

Oral administration of recombinant human acid α-glucosidase reduces specific antibody formation against enzyme in mouse

1 reference

12 December 2020

Reducing the immunogenicity of protein therapeutics

1 reference

12 December 2020

Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants

1 reference

12 December 2020

Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease

1 reference

12 December 2020

IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome

1 reference

12 December 2020

CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes

1 reference

12 December 2020

Plant-made vaccine antigens and biopharmaceuticals

1 reference

12 December 2020

Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa

1 reference

12 December 2020

Potential application of tregitopes as immunomodulating agents in multiple sclerosis

1 reference

12 December 2020

Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, o

1 reference

12 December 2020

Pentosan polysulfate: a novel therapy for the mucopolysaccharidoses

1 reference

12 December 2020

A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability

1 reference

12 December 2020

A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease

1 reference

12 December 2020

Hematopoietic stem cell transplantation improves the high incidence of neutralizing allo-antibodies observed in Hurler's syndrome after pharmacological enzyme replacement therapy.

1 reference

12 December 2020

Coupling pathogen recognition to innate immunity through glycan-dependent mechanisms

1 reference

12 December 2020

The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase.

1 reference

12 December 2020

Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment

1 reference

12 December 2020

Tolerogenic dendritic cells

1 reference

12 December 2020

Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease.

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

1 reference

12 December 2020

Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model

1 reference

12 December 2020

Enzyme replacement in a canine model of Hurler syndrome

1 reference

12 December 2020

Fabry disease, enzyme replacement therapy and the significance of antibody responses

1 reference

12 December 2020

Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey

1 reference

12 December 2020

Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience

1 reference

12 December 2020

Identification of an N-linked glycosylation in the C4 region of HIV-1 envelope gp120 that is critical for recognition of neighboring CD4 T cell epitopes

1 reference

12 December 2020

Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT.

1 reference

12 December 2020

Allo-immune membranous nephropathy and recombinant aryl sulfatase replacement therapy: a need for tolerance induction therapy

1 reference

12 December 2020

Antibody response in patients with Gaucher disease after repeated infusion with macrophage-targeted glucocerebrosidase

1 reference

12 December 2020

Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase).

1 reference

12 December 2020

Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease

1 reference

12 December 2020

Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase).

1 reference

12 December 2020

Treatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: the relevance of clinical trial end points

1 reference

12 December 2020

Transient low-dose methotrexate generates B regulatory cells that mediate antigen-specific tolerance to alglucosidase alfa

1 reference

12 December 2020

A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)

1 reference

12 December 2020

Permanent partial phenotypic correction and tolerance in a mouse model of hemophilia B by stem cell gene delivery of human factor IX.

1 reference

12 December 2020

Maintenance of cell surface glycan density by lectin-glycan interactions: a homeostatic and innate immune regulatory mechanism

1 reference

12 December 2020

CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A.

1 reference

12 December 2020

Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research

1 reference

12 December 2020

Severe infusion reactions to fabry enzyme replacement therapy: rechallenge after tracheostomy

1 reference

12 December 2020

The role of antibodies in enzyme treatments and therapeutic strategies

1 reference

12 December 2020

Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation

1 reference

12 December 2020

Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration

1 reference

12 December 2020

A revised home treatment algorithm for Fabry disease: influence of antibody formation

1 reference

12 December 2020

Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: A perspective from the Hunter Outcome Survey (HOS)

1 reference

12 December 2020

Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype

1 reference

12 December 2020

Non-depleting anti-CD4 monoclonal antibody induces immune tolerance to ERT in a murine model of Pompe disease

1 reference

12 December 2020

Regulatory B cells: origin, phenotype, and function.

1 reference

12 December 2020

Dendritic cell control of tolerogenic responses

1 reference

12 December 2020

Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease.

1 reference

12 December 2020

Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products

1 reference

12 December 2020

Heparin cofactor II-thrombin complex and dermatan sulphate:chondroitin sulphate ratio are biomarkers of short- and long-term treatment effects in mucopolysaccharide diseases

1 reference

12 December 2020

Effects of protein aggregates: an immunologic perspective

1 reference

12 December 2020

Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome).

1 reference

12 December 2020

Anti-TNF-alpha therapy enhances the effects of enzyme replacement therapy in rats with mucopolysaccharidosis type VI

1 reference

12 December 2020

Toll-like receptor control of the adaptive immune responses

1 reference

12 December 2020

On the Role of Aggregates in the Immunogenicity of Recombinant Human Interferon Beta in Patients with Multiple Sclerosis

1 reference

12 December 2020

Immunological cell type characterization and Th1-Th17 cytokine production in a mouse model of Gaucher disease

1 reference

12 December 2020

An individually, modified approach to desensitize infants and young children with Pompe disease, and significant reactions to alglucosidase alfa infusions

1 reference

12 December 2020

Enzyme replacement therapy induces T-cell responses in late-onset Pompe disease

1 reference

12 December 2020

Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins

1 reference

12 December 2020

Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial

1 reference

12 December 2020

Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase

1 reference

12 December 2020

Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease

1 reference

12 December 2020

Immune response hinders therapy for lysosomal storage diseases

1 reference

12 December 2020

Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease

1 reference

12 December 2020

Caveat to protein replacement therapy for genetic disease. Immunological implications of accurate molecular diagnosis

1 reference

12 December 2020

The effect of insulin antibodies on insulin dose and diabetic control

1 reference

12 December 2020

T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation

1 reference

12 December 2020

Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7

1 reference

12 December 2020

Elimination of antibodies to recombinant enzyme in Pompe's disease.

1 reference

12 December 2020

Safety and efficacy of enzyme replacement therapy with idursulfase beta in children aged younger than 6 years with Hunter syndrome.

1 reference

12 December 2020

Successful Desensitisation in a Patient with CRIM-Positive Infantile-Onset Pompe Disease.

1 reference

12 December 2020

Indications et mécanismes d’action des immunoglobulines intraveineuses dans les pathologies auto-immunes et inflammatoires systémiques

1 reference

12 December 2020

CRIM-negative infantile Pompe disease: 42-month treatment outcome.

1 reference

12 December 2020

Role of B cells in tolerance induction

1 reference

12 December 2020

Polymorphisms in the F8 gene and MHC-II variants as risk factors for the development of inhibitory anti-factor VIII antibodies during the treatment of hemophilia a: a computational assessment

1 reference

12 December 2020

Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor?

1 reference

12 December 2020

Successful induction of immune tolerance to enzyme replacement therapy in canine mucopolysaccharidosis I

1 reference

12 December 2020

Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome

1 reference

12 December 2020

Methotrexate reduces antibody responses to recombinant human alpha-galactosidase A therapy in a mouse model of Fabry disease

1 reference

12 December 2020

Role of physiology in the determination of protein heterogeneity

1 reference

12 December 2020

A large-scale computational study of inhibitor risk in non-severe haemophilia A.

1 reference

12 December 2020

Innate and Adaptive Immune Response in Fabry Disease

1 reference

12 December 2020

Laboratory assessment of factor VIII inhibitor titer: the North American Specialized Coagulation Laboratory Association experience

1 reference

12 December 2020

Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease.

1 reference

12 December 2020

10.1007/S10545-016-9917-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26883220%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference